CRON
Price
$3.44
Change
+$0.05 (+1.47%)
Updated
Oct 22, 04:59 PM (EDT)
Capitalization
1.25B
14 days until earnings call
Intraday BUY SELL Signals
UPC
Price
$4.42
Change
+$0.44 (+11.06%)
Updated
Oct 22 closing price
Capitalization
20M
Intraday BUY SELL Signals
Interact to see
Advertisement

CRON vs UPC

CRON vs UPC Comparison Chart in %
loading
loading
View a ticker or compare two or three
VS
CRON vs. UPC commentary
Oct 23, 2026

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is CRON is a StrongBuy and UPC is a Hold.

Interact to see
Advertisement
SUMMARIES
A.I.Advisor
a Summary for CRON with price predictions
Oct 21, 2026

CRON sees its Stochastic Oscillator ascending out of oversold territory

On October 19, 2026, the Stochastic Oscillator for CRON moved out of oversold territory and this could be a bullish sign for the stock. Traders may want to buy the stock or buy call options. Tickeron's A.I.dvisor looked at 80 instances where the indicator left the oversold zone. In 66 of the 80 cases the stock moved higher in the following days. This puts the odds of a move higher at over 82%.

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

The Momentum Indicator moved above the 0 level on October 21, 2026. You may want to consider a long position or call options on CRON as a result. In 81 of 106 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 76%.

The Moving Average Convergence Divergence (MACD) for CRON just turned positive on October 21, 2026. Looking at past instances where CRON's MACD turned positive, the stock continued to rise in 47 of 59 cases over the following month. The odds of a continued upward trend are 80%.

CRON moved above its 50-day moving average on October 20, 2026 date and that indicates a change from a downward trend to an upward trend.

Following a +4.31% 3-day Advance, the price is estimated to grow further. Considering data from situations where CRON advanced for three days, in 168 of 229 cases, the price rose further within the following month. The odds of a continued upward trend are 73%.

Bearish Trend Analysis

The 10-day moving average for CRON crossed bearishly below the 50-day moving average on October 13, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In 14 of 19 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are 74%.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where CRON declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 76%.

CRON broke above its upper Bollinger Band on October 21, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.

Fundamental Analysis (Ratings)

The Tickeron Price Growth Rating for this company is 41 (best 1 - 100 worst), indicating steady price growth. CRON’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron Valuation Rating of 52 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (1.169) is normal, around the industry mean (11.138). P/E Ratio (17.842) is within average values for comparable stocks, (-7.600). Projected Growth (PEG Ratio) (0.020) is also within normal values, averaging (2.152). Dividend Yield (0.000) settles around the average of (0.038) among similar stocks. P/S Ratio (6.993) is also within normal values, averaging (178.797).

The Tickeron SMR rating for this company is 80 (best 1 - 100 worst), indicating slightly better than average sales and a considerably profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron PE Growth Rating for this company is 94 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. CRON’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 84, placing this stock worse than average.

A.I.Advisor
a Summary for UPC with price predictions
Oct 21, 2026

Momentum Indicator for UPC turns negative, indicating new downward trend

UPC saw its Momentum Indicator move below the 0 level on September 30, 2026. This is an indication that the stock could be shifting in to a new downward move. Traders may want to consider selling the stock or exploring put options. Tickeron's A.I.dvisor looked at 89 similar instances where the indicator turned negative. In 82 of the 89 cases, the stock moved further down in the following days. The odds of a decline are at 90%.

Price Prediction Chart

Technical Analysis (Indicators)

Bearish Trend Analysis

The Moving Average Convergence Divergence Histogram (MACD) for UPC turned negative on October 01, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 43 similar instances when the indicator turned negative. In 37 of the 43 cases the stock turned lower in the days that followed. This puts the odds of success at 86%.

UPC moved below its 50-day moving average on September 21, 2026 date and that indicates a change from an upward trend to a downward trend.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where UPC declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 90%.

The Aroon Indicator for UPC entered a downward trend on October 21, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.

Bullish Trend Analysis

The RSI Oscillator points to a transition from a downward trend to an upward trend -- in cases where UPC's RSI Oscillator exited the oversold zone, 30 of 39 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 77%.

The Stochastic Oscillator shows that the ticker has stayed in the oversold zone for 15 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an upward trend is expected.

Following a +4.91% 3-day Advance, the price is estimated to grow further. Considering data from situations where UPC advanced for three days, in 180 of 214 cases, the price rose further within the following month. The odds of a continued upward trend are 84%.

UPC may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.

Fundamental Analysis (Ratings)

The Tickeron PE Growth Rating for this company is 32 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Valuation Rating of 33 (best 1 - 100 worst) indicates that the company is slightly undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (0.748) is normal, around the industry mean (11.138). P/E Ratio (-0.001) is within average values for comparable stocks, (-7.600). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (2.152). Dividend Yield (0.000) settles around the average of (0.038) among similar stocks. P/S Ratio (0.150) is also within normal values, averaging (178.797).

The Tickeron Price Growth Rating for this company is 64 (best 1 - 100 worst), indicating fairly steady price growth. UPC’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron SMR rating for this company is 98 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. UPC’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 84, placing this stock worse than average.

FUNDAMENTALS RATINGS
CRON: Fundamental Ratings
CRON
OUTLOOK RATING
1..100
28
VALUATION
overvalued / fair valued / undervalued
1..100
52
Fair valued
PROFIT vs RISK RATING
1..100
100
SMR RATING
1..100
80
PRICE GROWTH RATING
1..100
41
P/E GROWTH RATING
1..100
94
SEASONALITY SCORE
1..100
n/a

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

TECHNICAL ANALYSIS
Technical Analysis
CRONUPC
RSI
ODDS (%)
N/A
Bullish Trend 2 days ago
77%
Stochastic
ODDS (%)
Bullish Trend 2 days ago
82%
Bullish Trend 2 days ago
87%
Momentum
ODDS (%)
Bullish Trend 2 days ago
76%
Bearish Trend 2 days ago
90%
MACD
ODDS (%)
Bullish Trend 2 days ago
80%
Bearish Trend 2 days ago
86%
TrendWeek
ODDS (%)
Bullish Trend 2 days ago
79%
Bearish Trend 2 days ago
90%
TrendMonth
ODDS (%)
Bullish Trend 2 days ago
77%
Bearish Trend 2 days ago
90%
Advances
ODDS (%)
Bullish Trend 2 days ago
73%
Bullish Trend 10 days ago
84%
Declines
ODDS (%)
Bearish Trend 9 days ago
76%
Bearish Trend 3 days ago
90%
BollingerBands
ODDS (%)
Bearish Trend 2 days ago
84%
Bullish Trend 2 days ago
84%
Aroon
ODDS (%)
N/A
Bearish Trend 2 days ago
90%
COMPARISON
Comparison
Oct 23, 2026
Stock price -- (CRON: $3.39 vs. UPC: $3.98)
Brand notoriety: CRON and UPC are both not notable
Both companies represent the Pharmaceuticals: Generic industry
Current volume relative to the 65-day Moving Average: CRON: 104% vs. UPC: 297%
Market capitalization -- CRON: $1.27B vs. UPC: $22.21M
CRON [@Pharmaceuticals: Generic] is valued at $1.27B. UPC’s [@Pharmaceuticals: Generic] market capitalization is $22.21M. The market cap for tickers in the [@Pharmaceuticals: Generic] industry ranges from $2.12K to $68.49B. The average market capitalization across the [@Pharmaceuticals: Generic] industry is $4.33B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is overvalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

CRON’s FA Score shows that 0 FA rating(s) are green while UPC’s FA Score has 2 green FA rating(s).

  • CRON’s FA Score: 0 green, 5 red.
  • UPC’s FA Score: 2 green, 3 red.
According to our system of comparison, UPC is a better buy in the long-term than CRON.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

CRON’s TA Score shows that 5 TA indicator(s) are bullish while UPC’s TA Score has 4 bullish TA indicator(s).

  • CRON’s TA Score: 5 bullish, 3 bearish.
  • UPC’s TA Score: 4 bullish, 5 bearish.
According to our system of comparison, CRON is a better buy in the short-term than UPC.

Price Growth

CRON (@Pharmaceuticals: Generic) experienced а +7.28% price change this week, while UPC (@Pharmaceuticals: Generic) price change was -3.63% for the same time period.

The average weekly price growth across all stocks in the @Pharmaceuticals: Generic industry was -2.94%. For the same industry, the average monthly price growth was -9.84%, and the average quarterly price growth was +9.53%.

Reported Earning Dates

CRON is expected to report earnings on Nov 05, 2026.

Industries' Descriptions

@Pharmaceuticals: Generic (-2.94% weekly)

A generic drug contains the same chemical substance as a drug that was originally protected by patents. Generic drugs are generally sold at cheaper price points, compared to name-brand pharmaceuticals, after patents for the more expensive drugs lapse. The generic drug industry has created a major market, thanks to the lower pricing. According to the Center for Justice and Democracy at New York Law School, 80 percent of all drugs prescribed are generic, and generic drugs are chosen 94 percent of the time when they are available. But their manufacturers must be able to prove to the FDA that they can be effective substitutes for the original drugs. Some of the major generic drug makers include Zoetis, Inc., Allergan plc and Mylan N.V.

View a ticker or compare two or three
CRON
Daily Signal:
Gain/Loss:
UPC
Daily Signal:
Gain/Loss:
Interact to see
Advertisement

CRON and

Correlation & Price change

A.I.dvisor indicates that over the last year, CRON has been closely correlated with SNDL. These tickers have moved in lockstep 73% of the time. This A.I.-generated data suggests there is a high statistical probability that if CRON jumps, then SNDL could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To CRON
1D Price
Change %
CRON100%
+3.35%
SNDL - CRON
73%
Closely correlated
N/A
ACB - CRON
60%
Loosely correlated
-0.25%
CGC - CRON
60%
Loosely correlated
-6.67%
TLRY - CRON
58%
Loosely correlated
-3.63%
TRLV - CRON
55%
Loosely correlated
+1.95%
More
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
AMWL13.970.77
+5.83%
American Well Corp
UNF274.007.37
+2.76%
Unifirst Corp
TER345.498.90
+2.64%
Teradyne
GPUS0.14N/A
-3.25%
Hyperscale Data Inc.
ODD22.38-1.15
-4.89%
ODDITY Tech Ltd